AF	Atrial fibrillation
ATRIA	AnTicoagulation and Risk factors In Atrial fibrillation
AUC	Area under the curve
CHADS2	Congestive heart failure, hypertension, age ≥ 75 years, diabetes, stroke/transient ischemic attack/thromboembolism [doubled]
CHA2DS2-VASc	Congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65–75 years, sex category [female]
CRUSADE	Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines
DACH	Germany (Deutschland), Austria, Switzerland (Confederatio Helvetica)
eCRF	Electronic case report form
GOF	Hosmer and Lemeshow goodness-of-fit test
GRACE	Global Registry of Acute Coronary Events
HAS-BLED	hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio [INR], elderly [age ≥ 65 years], drugs/alcohol concomitantly
IDI	Integrated discrimination improvement
ISTH	International Society on Thrombosis and Haemostasis
NRI	Net reclassification improvement
NOAC	non-vitamin K antagonist oral anticoagulant
PREFER in AF	Prevention of Thromboembolic Events—European Registry in Atrial Fibrillation” study
SD	Standard deviation of the mean
SEE	Systemic embolic event
TIA	Transient ischemic attack
TIMI	Thrombolysis In Myocardial Infarction
VKA	Vitamin K antagonist